Epizyme, Inc. is a clinical stage biopharmaceutical company that focuses on developing epigenetic therapies for cancer patients. The company's product platform creates small molecule inhibitors of a 96-member class of enzymes known as histone methyltransferases (HMTs). Epizyme's proprietary technology allows it to discover and develop novel drugs targeting these enzymes, which are known to play a critical role in cancer growth and progression. With a pipeline of promising drug candidates, Epizyme is well-positioned to address unmet medical needs in oncology, helping to advance the fight against cancer.